Supernus Mourns the Loss of Board Member William Nuerge
January 12 2018 - 3:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), It is with great
sadness that Supernus announces that William Nuerge, a valued
member of its Board of Directors, passed away on January 10, 2018.
Mr. Nuerge had a long and distinguished career in the
pharmaceutical industry, including serving as CEO of Shire US and
Xanodyne Pharmaceuticals until his retirement. Mr. Nuerge joined
the Supernus Board of Directors in 2006.
"We are deeply saddened by the passing of Bill, a colleague and
a long-time friend who will be sorely missed," said Jack Khattar,
President and CEO, Supernus. "For eleven years, Bill contributed
greatly to Supernus through his broad business expertise and deep
knowledge of operational performance. Bill's death is a tragedy for
his family and a great loss to our company. I greatly appreciated
his wisdom and counsel on company matters. Our thoughts and prayers
are with his family and friends."
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy, and Oxtellar
XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
The Company is also developing several product candidates to
address large market opportunities in psychiatry, including SPN-810
for the treatment of Impulsive Aggression in ADHD patients and
SPN-812 for the treatment of ADHD.
Contact:Jack A. Khattar, President and
CEOGregory S. Patrick, Vice President and CFOSupernus
Pharmaceuticals, Inc.301-838-2591
Or
Investor Contact:Peter VozzoWestwicke
PartnersOffice: (443) 213-0505Mobile: (443) 377-4767Email:
peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024